DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pralsetinib
Pralsetinib
Cstone's Partner Blueprint Medicines Presented Updated Part 1 Data from PIONEER Trial of Avapritinib
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
CHMP Agenda of the 19-22 April 2021 Meeting
Rxoutlook® 1St Quarter 2019
Presentación De Powerpoint
RET Inhibition in Novel Patient-Derived Models of RET Fusion
Progresses Toward Precision Medicine in RET-Altered Solid Tumors Carmen Belli1, Santosh Anand2,3, Justin F
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Strengthening the Accelerated Approval Pathway: an Analysis of Potential Policy Reforms and Their Impact on Uncertainty, Access, Innovation, and Costs
Molecular Profiling and Targeted Therapies for Older Patients with Advanced NSCLC
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Targeted Therapy for Lung Cancer (Faculty Presentations)
Blueprint Medicines.Pdf
Westfield USHP Slides Handout
PRECISION THAT MOVES™ Staying One Step Ahead of Disease
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer
Top View
Breakthroughs at Blueprint Medicines
Full Prescribing Information [FDA]
Using the Structural Kinome to Systematize Kinase Drug Discovery
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
E-Learning New Systemic Treatment Options for Radioiodine-Refractory Differentiated and Medullary Thyroid Cancers
Therapeutic Advances in Oncology
Pralsetinib (BLU-667) Demonstrates Robust Activity in RET-Fusion-Driven
Molecular Testing of Solid and Hematologic Tumors and Malignancies
CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals As of Decemeber 31, 2020
Into the Unknown: a Case of New-Onset Cardiomyopathy in a Patient Treated with Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib
Oncology Agents Policy #: Rx.01.67
Tumour-Agnostic Therapies
Optimizing Use of Biomarkers in Managing Metastatic Non−Small Cell Lung Cancer the Role of the Oncology Health Care Team Faculty Information
CHMP Agenda of the 25-29 January 2021 Meeting
Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET Fusion+ Solid Tumors
Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
11052021 MR ASCO 2021 Curtain Raiser
Clinical Activity and Safety of the RET Inhibitor
CY 2020 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2020
Comparative Assessment of Protein Kinase
Precision That Moves™
List Item Applications for New Human
Tyrosine Kinase Inhibitors - Oral
14072020 MR Roche Collaborates with Blueprint Medicines EN
Pralsetinib (Gavreto™) EOCCO POLICY
Selective RET Targeted Agents and RET Testing in Non-Small-Cell Lung Carcinoma (NSCLC)
Specialty Pipeline MONTHLY UPDATE
Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: a Literature Review
Analysis of Resistance Mechanisms to Pralsetinib (Blu-667) in Patients with Ret Fusion–Positive Non-Small Cell Lung Cancer (Nsclc) from the Arrow Study
2021 Interim Results Presentation
Selective Inhibitors for Cancer Patients
Download Overview
Pralsetinib Data Review and Registration Program Update
Progresses Toward Precision Medicine in RET-Altered Solid Tumors
Molecular Analysis for Targeted Therapy Or Immunotherapy of Non-Small-Cell Lung Cancer
409 Oncology Drugs
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
Advances in Targeting RET-Dependent Cancers
Tyrosine Kinase Receptors in Oncology
374-7580 FDA Approves Blueprint Medicines' AYVAKIT™ (Avapritinib)